TY - JOUR
T1 - Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma
T2 - Results from two transplant centres
AU - Smith, Stephen D.
AU - Moskowitz, Craig H.
AU - Dean, Robert
AU - Pohlman, Brad
AU - Sobecks, Ronald
AU - Copelan, Edward
AU - Andresen, Steven
AU - Bolwell, Brian
AU - Maragulia, Jocelyn C.
AU - Vanak, Jill M.
AU - Sweetenham, John
AU - Moskowitz, Alison J.
PY - 2011/5
Y1 - 2011/5
N2 - Prior series have demonstrated that early relapsed (within 1year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan-Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1year. Two hundred and fourteen patients were analysed and the event-free survival (EFS) and overall survival (OS) at 6years for all patients were 45% and 55%, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5cm). Patients with 0, 1, or 2 risk factors achieved 6year EFS of 65%, 47%, and 24% and 6year OS of 81%, 55%, and 27%, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies.
AB - Prior series have demonstrated that early relapsed (within 1year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan-Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1year. Two hundred and fourteen patients were analysed and the event-free survival (EFS) and overall survival (OS) at 6years for all patients were 45% and 55%, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5cm). Patients with 0, 1, or 2 risk factors achieved 6year EFS of 65%, 47%, and 24% and 6year OS of 81%, 55%, and 27%, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies.
KW - Hodgkin lymphoma
KW - Refractory
KW - Relapse
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=79953907334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953907334&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2011.08616.x
DO - 10.1111/j.1365-2141.2011.08616.x
M3 - Article
C2 - 21410449
AN - SCOPUS:79953907334
SN - 0007-1048
VL - 153
SP - 358
EP - 363
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -